Research for China $1.8 Billion Jiangsu Sinopep-Allsino Biopharmaceutical Fined $6.6 Million & Issued with Delisting Warning for Inflating Revenue ($4.2 Million) & Profit ($3.6 Million) in 2021 Which Also Allowed Company to Issue $60 Million Convertible Bonds in 2023, Senior Executives Fined from $209,000 to $2.5 Million with ex-Vice Chairman & Actual Controller Dezhong Zhao Fined $2.5 Million (CNY 18 Million), Founded in 2009 by Zi Quan Tong, IPO on Shanghai Stock Exchange in 2021 - aVenture Research
Caproasia | Driving $28 trillion assets in Asia | The leading financial media platform in Asia covering capital markets, investments & private wealth
China $1.8 Billion Jiangsu Sinopep-Allsino Biopharmaceutical Fined $6.6 Million & Issued with Delisting Warning for Inflating Revenue ($4.2 Million) & Profit ($3.6 Million) in 2021 Which Also Allowed Company to Issue $60 Million Convertible Bonds in 2023, Senior Executives Fined from $209,000 to $2.5 Million with ex-Vice Chairman & Actual Controller Dezhong Zhao Fined $2.5 Million (CNY 18 Million), Founded in 2009 by Zi Quan Tong, IPO on Shanghai Stock Exchange in 2021
China Jiangsu Sinopep-Allsino Biopharmaceutical ($1.8 billion market value) has been fined $6.6 million & issued with delisting warning for inflating revenue ($4.2 million) & profit ($3.6 million) in 2021, which also allowed company to issue $60 million convertible bonds in 2023. Senior executives were fined from $209,000 to $2.5 million with ex-Vice Chairman & actual controller Dezhong Zhao fined $2.5 million (CNY 18 million). Jiangsu Sinopep-Allsino Biopharmaceutical was founded in 2009 by Zi